Introduction
Intracranial localization is reported in <1% of cases of multiple myeloma [1] , with pachymeningeal and leptomeningeal lesions associated with hematogenous spread [2] . Interestingly, the incidence of central nervous system (CNS) myeloma has been increasing, which may be reflective of new chemotherapeutic agents used to treat the primary manifestation [3] . Our workup revealed no lesions other than a questionable T2 spinal process lesion. We performed a right-sided excisional biopsy of a superficial temporal lesion to establish the diagnosis, which confirmed the presence of plasmacytoid cells.
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Discussion
In a recent review, 7 patients who underwent stem cell transplant and treatment with novel agents for multiple myeloma developed intracranial disease [3] . Our case is an unusual presentation of isolated intracranial disease in conjunction with complete remission on sole bortezomib therapy (subsequent to induction combination chemotherapy) and no stem-cell transplant.
Conclusion
This case highlights the possibility that CNS manifestation may be related to potential lack of blood-brain barrier penetrance of novel agents [1] .
